Shares of Coherus BioSciences rose 4.5% to $1.8 in pre-market activity after it released positive med-stage results for its ...

The funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on fueling progress with OKYO's lead program, OK-101 focused on treating ...

Coherus BioSciences (CHRS) announced final data from its Phase 2 open label clinical trial evaluating casdozokitug, a selective and potent ...

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...

One of the best ways to address the gap between healthcare providers and patients is by making diagnostic processes more ...